Heart Failure
Conditions
Keywords
diuretic, oral, intravenous
Brief summary
The goal of this clinical study is to compare treatment regimens of loop diuretics in patients with decompensated heart failure. The main aim is to answer if early change from intravenous to oral loop diuretics is safe and effective.
Interventions
DRUGFurosemide Pill 150% equivalent iv dose
change from intravenous to oral furosemide
DRUGFurosemide Pill 200% equivalent iv dose
change from intravenous to oral furosemide
change from intravenous to oral furosemide
Sponsors
Jan Kochanowski University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient hospitalized due to exacerbation of heart failure symptoms, where AHF is the main cause of hospitalization. To be included in the study, all criteria 1 to 6 must be met: 1. Fluid Retention Features: * Described congestion above the lung fields on chest X-ray * rales on chest auscultation * Peripheral edema, yielding to pressure occurring within the limbs or the sacral part of the spine * Increased pressure in the jugular veins (\>=8 cm H2O) 2. The concentration of natiuretic peptides must be assessed within 24 hours of admission to the hospital and be: ✔ NTpro-BNP \>450 pg/mL for \<55 years, 900 pg/mL for 55-75 years, and \>1800 pg/mL for \>75 years 3. Exacerbation of heart failure treated with at least 40 mg of furosemide IV. (or 20 mg torasemide equivalent) 4. Left ventricular ejection fraction \< 50% (assessed and documented in the last 12 months prior to study entry) 5. Age \>= 18 years 6. The study participant gave and signed an informed consent to participate in the study. No medical procedure related to the study was performed prior to giving informed consent.
Exclusion criteria
* 1\. Shortness of breath caused by respiratory infection, exacerbation of bronchial asthma, COPD 2. Body temperature \> 38 C, signs of active infection requiring antibiotic therapy, sepsis, infective endocarditis 3. An episode of acute coronary syndrome, stroke or TIA within 6 months before randomization 4. Severe valvular disease requiring or in the process of qualifying for repair 5. Patients requiring dialysis (in the past, during hospitalization or in the process of qualifying for dialysis) 6. History of alcohol abuse in the last 2 years before randomization 7. Pregnancy or breastfeeding 8. Active cancer or in remission for less than 5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of patients requiring hospitalization | 12 weeks | any hospitalization due to cardiovascular reasons |
| Time to hospitalization measured in days | Up to 12 weeks | Time to any hospitalization due to cardiovascular reasons |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Death | 12 weeks | Cardiovascular death |
| New York Heart Association NYHA class | 6 and12 weeks | NYHA class assessment |
| assessment of quality of life | 12 weeks | QoL by Minnesota questionnaire |
Countries
Poland
Outcome results
None listed